Ossium Health Awarded $3.46M in Funding from the California Institute of Regenerative Medicine (CIRM) to Advance the Development of OSSM-007 for the Treatment of Steroid-Refractory Acute Graft versus Host Disease (GVHD)

Press Published by 3rd Party PR Representative on:  
Geney Kim
Ossium Health, Inc.
415-513-5535
press@ossiumhealth.com